Goldman Sachs Research Summary (JAN 5, 2007)
Goldman Sachs full research note summary:Pfizer (PFE) reinstated as Buy with $30 target.WellPoint (WLP) raised to Buy from Neutral, but Aetna (AET) cut to Neutral from Buy.Current fiscal estimates hiked on ACE, AHL, HCC, CB, PTP, RNR, XL by 1%…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Goldman Sachs full research note summary:
Pfizer (PFE) reinstated as Buy with $30 target.
WellPoint (WLP) raised to Buy from Neutral, but Aetna (AET) cut to Neutral from Buy.
Current fiscal estimates hiked on ACE, AHL, HCC, CB, PTP, RNR, XL by 1% to 2%. Current fiscal estimates trimmed slightly on Chicos FAS (CHS) and Dow Chemical (DOW).
Atmos Energy (ATO) started as Neutral.
Contact [email protected] for any questions or corrections.







